The FDA has issued a warning letter to NuVasive over certain marketing language regarding the company's Affix Spinous Process Plate System. NuVasive said in a regulatory filing that it is already beginning to address the issue, and the company stressed to its shareholders that there were no manufacturing problems that needed to be addressed.
NuVasive gets warning letter over spinal implant marketing
SmartBrief Job Listings for Health Care
|Chief Financial Officer||
B. E. Smith
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|